<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154488</url>
  </required_header>
  <id_info>
    <org_study_id>X4P-001-104</org_study_id>
    <nct_id>NCT04154488</nct_id>
  </id_info>
  <brief_title>A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Neutropenia Disorders</brief_title>
  <official_title>A Phase 1B, Open-Label, Multicenter Study of Mavorixafor in Patients With Severe Congenital Neutropenia and Chronic Neutropenia Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>X4 Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>X4 Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1b study will determine the safety and tolerability of mavorixafor in participants
      with severe chronic idiopathic neutropenia (CIN) and selected congenital neutropenia
      disorders. The anticipated enrollment is up to 45 participants.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2020</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Baseline (Day -1) up to end of study (Day 44)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Neutrophil Count (ANC) of Mavorixafor in Participants With Severe CIN in Combination With Steady-State Granulocyte-Colony Stimulating Factor (G-CSF)</measure>
    <time_frame>Time 0 (pre-dose, up to 15 minutes prior), 30, 60, and 90 minutes (each ± 5 minutes) and 2, 3, 4, and 6 hours (each ± 15 minutes) post-dose at Day 1, 8, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve for ANC (AUCANC) of Mavorixafor in Participants With Severe CIN in Combination With Steady-State G-CSF</measure>
    <time_frame>Time 0 (pre-dose, up to 15 minutes prior), 30, 60, and 90 minutes (each ± 5 minutes) and 2, 3, 4, and 6 hours (each ± 15 minutes) post-dose at Day 1, 8, and 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Mavorixafor in Relation to ANC and AUCANC in Participants With Severe CIN</measure>
    <time_frame>Time 0 (pre-dose, up to 15 minutes prior), 30, 60, and 90 minutes (each ± 5 minutes) and 2, 3, 4, and 6 hours (each ± 15 minutes) post-dose at Day 1, 8, and 14</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Neutropenia</condition>
  <arm_group>
    <arm_group_label>Mavorixafor 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive mavorixafor 400 milligrams (mg) (4 capsules of 100 mg each) orally once daily (QD) in the morning for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavorixafor</intervention_name>
    <description>Mavorixafor capsules will be administered per dose and schedule specified in the arm.</description>
    <arm_group_label>Mavorixafor 400 mg</arm_group_label>
    <other_name>X4P-001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For all participants:

               -  Sign the informed consent form (ICF) and be willing and able to comply with the
                  protocol.

               -  Agree to use contraception as follows:

                  i) For women of childbearing potential (WOCBP): agree to use highly effective
                  contraceptive methods from screening through the study and for at least 4 weeks
                  after the last dose of study drug.

        ii) For male participants: agree to use a condom with any WOCBP sexual partner from
        screening through the study and for at least 4 weeks after the last dose of study drug.

          -  Participants with severe chronic idiopathic neutropenia (CIN):

               -  Be at least 18 years of age.

               -  Have a history of ANC less than (&lt;) 500 cells/microliter (μL), lasting for more
                  than 3 months at any time since diagnosis.

               -  Have been diagnosed with severe CIN more than 12 months ago that is not
                  attributable to medications, infectious, genetic, inflammatory, autoimmune, or
                  malignant causes.

               -  Be currently treated with a prophylactic steady-state G-CSF regimen for greater
                  than (&gt;) 15 days before receiving the first dose of study drug.

               -  Have normal cytogenetics on the most recent bone marrow biopsy/aspirate, if
                  performed.

               -  Have no associated thrombocytopenia nor anemia before G-CSF therapy initiation.

          -  Participants with selected congenital neutropenia conditions including GSD1b (GSD1b;
             SLC37A4), G6PC3 deficiency (G6PC3), or GATA2 deficiency (GATA2):

               -  Be at least 12 years of age.

               -  May be currently receiving steady-state G-CSF dosing or not have been on G-CSF
                  for &gt;15 days.

               -  Must have documentation of the mutational status before enrolling in the study.

        Exclusion Criteria:

          -  Known systemic hypersensitivity to the mavorixafor drug substance or its inactive
             ingredients.

          -  Diagnosis of cyclical neutropenia.

          -  Is pregnant or nursing.

          -  Known history of a positive serology or viral load for human immunodeficiency virus
             (HIV) or a known history of acquired immune deficiency syndrome.

          -  At screening, has laboratory test results meeting one or more of the following
             criteria:

               -  Positive hepatitis C virus (HCV) antibodies with confirmation by HCV-ribonucleic
                  acid polymerase chain reaction reflex testing.

               -  Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody
                  (HBcAb).

        Note: If a participant tests negative for HBsAg but positive for HBcAb, the participant
        would be considered eligible if the participant tests positive for antibody to HBsAg reflex
        testing.

          -  At screening, has laboratory test results meeting one or more of the following
             criteria:

               -  Hemoglobin &lt;10.0 grams/deciliter (g/dL)

               -  Platelet count &lt;175,000 cells/μL

               -  Mild/moderate renal impairment 30 to 60 glomerular filtration rate

               -  Serum aspartate transaminase &gt;2.5 * upper limit of normal (ULN)

               -  Serum alanine transaminase &gt;2.5 * ULN

               -  Total bilirubin &gt;1.5 * ULN (unless due to Gilbert's syndrome, in which case total
                  bilirubin greater than or equal to (≥) 3.0 * ULN and direct bilirubin &gt;1.5 * ULN)

          -  Within 2 weeks before Day 1, received any of the following treatments:

               -  Glucocorticoids (&gt;5 mg prednisone equivalent per day)

               -  Medication prohibited based on cytochrome P450 (CYP) and/or P-glycoprotein (P-gp)
                  interaction.

          -  At the planned initiation of study drug, has an uncontrolled infection requiring
             chronic or prophylactic use of antibiotics (systemic or inhaled) within 4 weeks before
             Day 1.

          -  Has any other medical or personal condition that, in the opinion of the Investigator,
             may potentially compromise the safety or compliance of the participant, or may
             preclude the participant's successful completion of the clinical study.

          -  Inability to ingest study drug as presented.

          -  Has a history of any hematologic malignancy.

          -  Diagnosed or suspected congenital long QT syndrome. Any history of clinically
             significant ventricular arrhythmias (such as ventricular tachycardia, ventricular
             fibrillation, or torsades de pointes); any history of arrhythmia will be discussed
             with the sponsor's medical monitor before participant's entry into the study.

          -  Prolonged corrected QT interval (QTc) using Fridericia's formula (QTcF) on pre-entry
             electrocardiogram (ECG) (≥450 milliseconds [ms]).

          -  Has an associated diagnosis of rheumatoid arthritis, systemic lupus erythematosus, or
             inflammatory bowel disease (IBD).

          -  Has been treated with G-CSF &gt;8 micrograms/kilogram/day (μg/kg/day) for more than 1
             consecutive month within the past 2 years and/or has been on G-CSF therapy &gt;10 years
             regardless of the dose.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patient Affairs and Advocacy</last_name>
    <phone>857-529-5779</phone>
    <email>patientinfo@x4pharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patient Affairs and Advocacy</last_name>
    <email>patientinfo@x4pharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>David C. Dale</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

